

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Ayati Devices raises Rs 15 Cr to scale AI-driven diabetic foot diagnostics platform

11 August 2026 | News

Ayati's technologies already hold regulatory clearances across major global markets



Ayati Devices, a Bengaluru-based medical technology and device manufacturing startup developing precision diagnostic solutions for diabetic foot complications and peripheral vascular disease, has raised Rs 15 Crore in a Pre-Series A funding round led by Inflexor Ventures.

This marks the company's first institutional investment and will accelerate the commercialisation of its next-generation diagnostic technologies, expand its domestic and international presence, strengthen manufacturing capabilities, and deepen investments in research, regulatory approvals, artificial intelligence, and global talent. Ayati Devices has been incubated at IITB-SINE as part of the institute's translational research programme.

Ayati's technologies already hold regulatory clearances across major global markets, including CDSCO (India), the US FDA, CE Mark (Europe), and approvals in Sri Lanka, Malaysia, and the UAE.

The company has deployed over 10,000 devices across 30+ countries, backed by a growing international distributor network and clinical deployments at leading institutions such as Medicovert Hospital and Aster Hospital.

The capital will fund Angiocam's commercialisation, expand go-to-market operations at home and abroad, strengthen manufacturing and supply chain capacity, accelerate R&D in AI-enabled diagnostics, secure further regulatory approvals, grow the IP portfolio, and build out engineering, clinical, regulatory, and global business development teams.

Looking ahead, Ayati will deepen its presence across Europe, the US, the Middle East, Southeast Asia, Australia, and Latin America through its distribution network, while evaluating direct commercial operations in key markets as demand scales. It will also expand its pay-per-test screening model across hospitals, primary care clinics, and community programmes, making preventive diagnostics far more accessible.